

CURRICULUM VITAE

2014

David M. Angaran, M.S., FCCP, FASHP

Clinical Professor of Pharmacy

University of Florida College of Pharmacy

Work Phone: (352) 273-6231

Work Fax: (352) 273-6498

E mail: anagaran@cop.ufl.edu

052314

CURRICULUM VITAE

NAME: David M. Angaran
TELEPHONE: (352) 264-9660 Home
FAX: (352) 264-0008 Home
HOME ADDRESS: 4083 NW 37 Terrace
Gainesville, FL 32606

EDUCATION:

Grandview College Des Moines, Iowa	September 1958 – June 1960 Junior College Degree
U.S. Air Force Pharmacy Technician	September 1961 – 1965
Drake University School of Pharmacy Des Moines, Iowa	September 1965 – June 1968 Bachelor of Science in Pharmacy
University of Wisconsin Hospitals and School Of Pharmacy Madison, Wisconsin	July 1968 – June 1970 Master of Science in Hospital Pharmacy and ASHP Residency

PROFESSIONAL EXPERIENCE**Clinical Professor of Pharmacy**

Jan 2013 Present

Development of MTM elective course. Contract with McGraw-Hill for the eText, Medication Therapy Management: A Comprehensive Approach, editors David Angaran and Karen Whalen, due out Fall 2014, Access Pharmacy.

MTMCCC consultant: MTM Contract review, new business evaluation, Medicaid mental health project and advisor to the Director of MTMCCC.

Community Healthcare Worker facilitating Medication Therapy Management. FLDOH and CDC Grant. Training program and practice model development. 2013-2015

Director, MTM Call Center

Jan 2010 to Jan 2013

Negotiated a \$2.55 million, 2 year, contract to provide MTM services for WellCare, a Tampa based insurance provider. Supervised the creation of a 24 seat call center that is currently, staffed with a Director, Assistant Director, 3 clinical faculty, a trainer, 3 staff pharmacists, an administrative assistant, resident, research fellow and 3 pharmacy technicians. The center currently provides MTM services for 10,000 ambulatory and LTC patients per year. The center has both a service and educational mission; providing year around clerkship experience for over 200 senior students and publishing research about the MTM experience. Responsible for the financial and academic success of the MTM call center through strategic planning, budget management, business development, recruitment of personnel and supporting research and publications.

Effective May 16th, 2011 was awarded a 3 year, \$323,000 contract, with State of Florida Agency for Health Care Administration, to deliver MTM services to 100 Medicaid patients. WellCare contract, \$1.42 million/year renewed on a continuing basis.

Assistant Director of Experiential Programs

June 2004-December 2009

Angaran Associates, LTD**Jan 2002-Jan 2004****Clients and Projects:**

- University of Florida, College of Pharmacy. Post Doc Fellow, Pharmacy HealthCare and Administration Dept.
- Tampa Patient Safety Center of Inquiry: An investigation of drug related physical injuries in a VA population. Analysis of concurrent medications and the relationship to falls and other injuries in 17,000 patients taking benzodiazepines.
- Visante, Inc: CE program development. Topics. Guidelines, Evidence Based Medicine, Competency assessment and Consumer Health Informatics.

Senior Director Interactive Health Communication

October 2000 – December 2001

Chronimed, Inc.
Minneapolis, Minnesota

Responsible for e-healthcare strategies, patient adherence/retention programs, customer satisfaction assessment and outbound telemarketing contacts. Chronimed is a specialty pharmacy provider, with 40 retail stores and mail service center, of high cost prescription

medications to patients with AIDS, Hepatitis C, Growth Hormone Deficiency, Rheumatoid Arthritis, Transplants, RSV and Hemophilia patients.

Chief Clinical Officer

January 2000 – July 2000

cranespharmacy.com
Minneapolis, Minnesota

The duties of chief clinical officer included the creation and management of a “Clinical Care Communication”(CCC) service that provided interactive health care communication in support of the Active Pharmacy services provided by cranespharmacy.com. The CCC concept included the integration of a multimedia contact center latest technologies, web based health content and interactive health communication techniques into a system that not only provided personalized information but also assessed comprehension.

Angaran Associates, LTD

February 1999 – January 2000

Columbus, Ohio

Consultant to: American Society of Health-system Pharmacist
AARP: Medication protocol development
Cranespharmacy.com

American Society of Health-System Pharmacists Managed Care Practitioner in Residence

February 1998 – January 1999

Washington, DC

Established telehealth contacts and recognition in the federal government, health care related professional organizations, telemedicine programs, telecommunication/ electronic communication industry and health care provider organizations.

Reviewed, evaluated and interpreted all the current literature related to telehealth.

Made telepharmacy presentations to numerous health care related organizations.

Published white paper: Angaran DM. Telemedicine and Telepharmacy: Current Status and future implications. Am J Health-Syst Pharm. 1999; 56:1405-26.

V.P. Clinical Practice and Education

September 1995 – December 1997

Merck-Medco Managed Care, LLC
Columbus, Ohio

Developed telephone based, pharmacist and nurse provided disease and demand management intervention programs. Responsible for five pharmacist practitioner/educators who provided clinical decision support and training to support the intervention programs.

- Created the clinical practice model, developed medication information content and conducted training/certification program for Senior Drug Use Review program as expansion of Partners for Health Aging.
- Proposed, designed, developed and evaluated the Personal Medication Review program, a complete therapeutic history. **Patient granted # 6,014,631.**
- Clinical pharmacy consultant for Well Informed demand management service, which combined a nurse triage service (CareWise, Inc.) and pharmacy contact center (Merck-Medco) for the purpose of providing both symptom triage and drug information. **Patent: 6,356,873**

Professor, acting Chair
Associate Director of Lawrence Dubow Center for

Sept 1993-Aug 1995

Pharmaceutical care

Professor, Chairman
Department of Pharmacy Practice
Associate Director, Department of Pharmacy
Shands Hospital
University of Florida
Gainesville, Florida

July 1990 – August 1993

Associate Professor, College of Pharmacy
Clinical Pharmacist, University Hospital
University of Minnesota
Minneapolis, Minnesota

July 1979 – June 1990

Director of Biomedical Research
United Hospitals, Inc.
St. Paul, Minnesota

November 1986 – June 1989

Clinical Pharmacist
United Hospitals, Inc.
St. Paul, Minnesota

July 1979 – June 1989

Director
Professional Practice Unit and Pharm.D. Program
University of Minnesota
Minneapolis, Minnesota

July 1976 – June 1979

Clinical Assistant Professor
School of Pharmacy
University of Wisconsin
Madison, Wisconsin

July 1973 – July 1976

PROFESSIONAL EXPERIENCE

Clinical Instructor School of Pharmacy University of Wisconsin Madison, Wisconsin	July 1970 – June 1973
Assistant to the Dean for Undergraduate Students School of Pharmacy University of Wisconsin Madison, Wisconsin	July 1971 – June 1972
Coordinator of All Clinical Instruction School of Pharmacy University of Wisconsin Madison, Wisconsin	July 1970 – July 1976

CONSULTANTSHIPS, COMMITTEES, EDITORIAL BOARDS

Personal Health Record Working Group: Apha representative: FACCT and Markle Foundation 2004

NCQA : HMO quality of patient access performance indicators: 2001-2003.

Achieving Pharmaceutical Care through Personal Skills Development, Executive Editor, 1992

Challenges in Pharmaceutical Care, National Chair, Bristol-Myers-Squibb, 1992

PEW Health Professions Commission, Pharmacy Advisory Panel, 1991

ACPE Accreditation Team (MSUC), March 19-21, 1991

Partners in Pharmaceutical Care, Contributing Editor, January 1991

Clinical Outcomes: Managing Patients and the Total Cost of Care, Editorial Advisory Board, 1990

ACCP, Editorial Board of Pharmacotherapy Self-Assessment Program (PSAP), 1990-93

Administrative and Practice Trends in Pharmaceutical Care, Contributing Editor, September 1989-September 1990

JCAHO Medication Use Task Force, Consultant, September 1989-1992

JCAHO Fellowship – Agenda for Change, Department of Outcomes and Research Development, September 1989-February 1990

American Health Care Systems, Consultant, 1987-1989

University of Pittsburgh, College of Pharmacy Clinical Programs, Consultant, 1987

ACCP, Public and Professional Relations Committee, 1986-1988

MSHP, Chairman, Public Relations Committee, 1986-1987

American Heart Association, St. Paul, Minnesota, Public Relations Committee, 1986-1987

American Critical Care, Esmolol, Consultant, 1985-1986

CONSULTANTSHIPS, COMMITTEES, EDITORIAL BOARDS

McNeil Pharmaceutical Advisory Board, Consultant, 1985

APHA Board of Pharmaceutical Specialties, Radiopharmaceutical, 1986-1987

Topics in Pharmacy Management, Editorial Board, 1982-1985

Clinical Pharmacy, Editorial Board, July 1981-December 1985

Kellogg Clinical Scientist Program, University of Minnesota, Director of Clinical Education, 1979-1985

University of Minnesota, Biomedical Ethics Institute, Advisory Panel, 1984-1986

Albany College of Pharmacy, proposed Pharm.D. program, Consultant Reviewer, June 1984

ACCP, Committee on Clinical Pharmacy as a Specialty, Development of Specialty Petition, 1982-1985

USP Open Conference on Parenteral Products, Co-Chairman, Compounding and Delivery Systems, March 1983

AACP, Committee on External Pharm.D. Degree, 1982-1983

ASHP, Council of Education and Manpower, 1980-1983; Chairman, 1982-1983

Drug Intelligence and Clinical Pharmacy, Editorial Board, December 1974-1982

GRANTS, CONTRACTS and PATENTS

MTM WellCare, Inc: \$1.42 million 2012 and beyond.

Adherence WellCare, Inc: \$100,000.00 Aug-December 2012

MED-ADS AHCA \$323,000 2011-2013

Medication Therapy Management: WellCare, Inc \$2,600,000 2010-2011

Personal Medication Review program **Patient # 6,014,631.**

Symptom and medication triage program: **Patent: 6,356,873**

Bristol-Myers-Squibb Pharmaceutical Care Fellowship, \$60,000. 1992-1994.

Marion Merrell Dow, Inc., \$21,000. Educational Program Support. 1991.

Upjohn, Co., \$12,600. Support for G. Vining, Phenytoin Indicator Development. 1991.

Marion Merrell Dow, Inc., \$50,000. Educational Program Support. 1991.

Veterans Affairs, \$18,000. Support J. Davis, Phenytoin Indicator Project. 1991.

Merck, Sharpe & Dohme, \$1,600. Program Attendance National Demonstration Project. 1991.

Shands Hospital (Shared 50%) \$10,000. Support for Critical Care Resident, Todd Wragge, Pharm.D. 1991.

Health Sciences Institute, \$22,000. JCAHO Fellowship Support. December 1989-February 1990.

Marion Laboratories-JCAHO, \$20,000. JCAHO Fellowship Support. September-November 1989.

Marion Laboratories-ASHP, \$16,500. Pharmaceutical Care: Ensuring Quality Outcomes Symposium, ASHP Midyear, 1989.

Ross Laboratories/Miles Pharmaceuticals, \$10,000. Influences of two enteral feedings on ciprofloxacin absorption, 1989.

GRANTS AND CONTRACTS

Marion Laboratories, \$20,000. The history of clinical pharmacy, Audio-visual production, in cooperation with ACCP. 1988-1989.

Marion Laboratories, \$43,000. The efficacy and safety of diltiazem/captopril combination compared to each agent alone and placebo in mild to moderate hypertension. 1988.

American Healthcare Systems, \$40,000. The establishment of a multi-hospital research consortium using a purchasing group membership. 1988.

Laboratory of Applied Pharmacokinetics. University of Southern California, Dr. Roger Jellitte. The pharmacokinetic modeling of lidocaine during coronary bypass surgery. 1988.

Glaxo, Inc., \$3,000. A multi-center evaluation of IV ranitidine usage, 1988.

Eli Lilly, \$40,000. Randomized, double-blind, crossover study compares dobutamine hydrochloride with dobutamine lactobionate in patients in the UH ICU with heart failure. 1988.

Data Med. Comparative trial of computerized warfarin dosing program using both an iterative and Bayesian predictive methods. 1987-1988.

G.H. Besselaar, \$52,000. A randomized, double-blind, multi-center trial comparing Benazepril (CGS-14824A) to digoxin and placebo as add-on therapy to diuretics in CHF. 1987.

Cherne Medical, Inc., \$20,000. The Cherne Heart Analyzer trial in the detection of resting ischemia. 1987-1989.

Squibb, \$44,000. Zoefenopril versus enalapril in the treatment of HTN with renal impaired patient. 1987.

N.I.H. Cardiac arrhythmia suppression trail with Hennepin County Hospital. 1987-1992.

Pharmaccia Company, \$2,500. The Deltec Infusion pump to deliver NTG Infusions. 1987.

United Hospital. Evaluation of the effect of heparin on lidocaine protein binding in red blood cell uptake. 1987-1988.

United Hospital, \$36,000. Influence of cardiopulmonary bypass surgery on lidocaine kinetics using stable isotope methodology. 1987-1988.

United Hospital, \$12,000. Comparison of continuance bioimpedance cardiac output with thermodilution, the Fick method, and venous oximetry. 1987-1988.

Marion Laboratories, \$40,000. A double-blind placebo controlled trial of intravenous diltiazem in the treatment of SVT. 1985-1987.

Smith Kline and French, \$36,000. Effect of cefonicid on prothrombin times in patients receiving maintenance warfarin therapy. 1985.

American Critical Care, \$40,000. The transfer of SVT patients from esmolol to alternative therapeutic agents – open label – safety efficacy. 1984-1986.

Merck, Sharpe and Dohme, \$11,000. Doloboid vs. acetaminophen #3 in postoperative hemorrhoid pain. 1984-1985.
GRANTS AND CONTRACTS

United Hospitals, \$4,000. Theophylline pharmacokinetics in the critically ill. 1984.

Stuart Labs, \$55,000. A double-blind placebo-controlled comparison of atenolol/propranolol/placebo in the prevention of arrhythmias in the postoperative CAB patient. 1983-1985.

United Hospitals, \$58,000. Drug Assay Research Laboratory in conjunction with Dr. William Natale, Pathologist. 1983-1985.

American Critical Care, \$35,000. Effect of infusion of esmolol in patients with SVT – an open label, one-day, safety-efficacy study. 1983-1984.

Argyle Laboratories, \$8,000. The relationship of chest tube stripping to ventricular tachycardia in post-CAB patients. 1983.

Eli Lilly, \$10,000. The influence of prophylactic antibiotics on warfarin anticoagulation therapy in prosthetic valve patients. 1983.

University of Minnesota College of Pharmacy, \$5,000. Ventricular arrhythmias in the postoperative CAB patient. 1982.

CLINICAL RESEARCH FELLOWS and Residents

2012: Lauren Stanchak and Alex Miguel

2011: Vinita Patel

2010: Jeffrey Lasczyk and Reena Mistry

1993: Maria Mirrales, PhD.

1992: Amy Broeseker, Pharm.D., R.N.

1989: Beth Noer, Pharm.D., Clinical Pharmacist, University of Illinois, College of Pharmacy, Chicago, Illinois.

1988: Donna Schmidt, Pharm.D., Director Drug Utilization Review, Vantage HMO.

1987-89: Alan Copa, Pharm.D., Clinical Pharmacist, Methodist Hospital, Indianapolis, Indiana.

1986: Mary Jane Watson, Pharm.D., Director of Clinical Research, Minnesota Research Center, Minneapolis, Minnesota.

1985: Dianne Brundage, Pharm.D., Methodist Hospital, St. Louis Park, Minnesota.

1985: Virgil Dias, Pharm.D., Senior Clinical Investigator, Marion Laboratories.

- 1984 Nate Schultz, Pharm.D., Director, Drug Utilization Review, United Health Care Corporation.
- 1983 Adrienne Ross, Pharm.D., Clinical Research Associate, E.R. Squibb & Sons.
- 1982 Abdulaziz Saddique, Pharm.D., Director of Pharmacy, King Khalid Hospital, Saudi Arabia.

CRITICAL CARE RESIDENT

- 1992 Todd Wragge, Pharm.D., Clinical Pharmacist, Barnes Hospital, St. Louis, Missouri.
- 1993 Bryan Southwood, Pharm D Clinical Pharmacist, University of Georgia

MAJOR PUBLICATIONS

RESEARCH AND REVIEW

Angaran DM. The Clinical Pharmacy Handbook. Wisconsin Hospitals, Department of Pharmacy, 1970-72.

Angaran DM, Bond CA. Procedure for Obtaining Medication Histories. University of Wisconsin Extension. Audiovisual Cassette Movie, October 1974.

Angaran DM. Introductory Aspects of Clinical Pharmacy. University of Wisconsin Extension, 1972; 8-cassette tape series, translated Japanese, Kobe, Japan, 1975.

Tape 1 – Clinical Practice Secundum Artem (50 min. each)

Tape 2 – Medical Terminology

Tape 3 – Diagnostic Lab Tests I

Tape 4 – Diagnostic Lab Tests II

Tape 5 – Over-the-Counter Urine Tests

Tape 6 – Neonatal and Pediatric Therapy

Tape 7 – Geriatric Therapy

Tape 8 – Body Function in Relation to Drug Therapy

Griefenhagen R, Jensen NM, Angaran DM, Ziltz DA. Flow Charts as Adjuncts to Symptomatic Screening. J. Am. Pharm. Assoc., 15:193-197. April 1975.

Angaran DM. Patient Monitoring: Proceedings of the First International Congress on Clinical Pharmacy Education, published AACP, 1976, pp. 106-108.

Angaran DM. Fluid and Electrolytes: A Practical Guide to Therapy. University of Wisconsin Extension, 8-cassette tape series, 1976.

Tape 1 – Introduction (50 min. each)

Tape 2 – Evaluation and Monitoring Parameter

Tape 3 – Blood Gases

Tape 4 – Metabolic Alkalosis

Tape 5 – Metabolic Acidosis

Tape 6 – Potassium Balance

Tape 7 – Sodium Disturbance

Tape 8 – Total Parenteral Nutrition

Angaran DM, Wise RL, Birnbaum ML. Hazards of Mechanical Ventilation: Therapeutic Implications. Am. J. Hosp. Pharm., 34:363-366, April 1976.

Angaran DM. Geriatric Therapy. Minnesota Pharmacist, 30:10-12, August 1976.

Reprinted: Texas Pharmaceutical Journal.

Angaran DM. Heading Off Adverse Reactions – Theophylline. Current Prescribing, 3:60-65, June 1977.

Peterson CD, Katz BL, Angaran DM. Ticarcillin and Carbenicillin. Drug Intel. Clin. Pharm., 11:482-486, August 1977.

Angaran DM. The Treatment of Cough and Cold, Pharmat, Inc., Matchet TA, Editor, March 1978.

MAJOR PUBLICATIONS

RESEARCH AND REVIEW

Bond CA, Angaran DM. Simulated Clinical Testing for Clinical Pharmacy and Therapeutics Course. Am. J. Pharm. Ed., 42:126-129, May 1978.

MacCara M, Angaran DM. Cephalothin, Cefazolin, Cephadrine: Interaction with Clinitest. Am. J. Hosp. Pharm., 35:1064-1067, September 1978.

Angaran DM. Critical Care Medicine, in “The Practice of Pharmacy,” Chapter 21, McLeod and Miller, PIL&P, 1980.

Angaran DM, Smith DS, Birnbaum M. The Use of Urine Test for Indirect Estimation of Blood Glucose Levels in the Critically Ill. Am. J. Hosp. Pharm., 37:950-956, July 1980.

Manning S, Angaran DM, Arom KV, et al. Intermittent intravenous potassium therapy in cardiopulmonary bypass patients. Clin. Pharmacy, 1:234-238, May-June 1982.

Arom KV, Angaran DM, Lindsay WG, et al. Effect of sodium nitroprusside during the payback of cardiopulmonary bypass on the incidence of postoperative arrhythmias. Annals of Thoracic Surgery, Vol. 34, 3:307-312, September 1982.

Angaran DM, Blissenbach HB. The Impact of Clinical Pharmacy on Administrative Structure and Function in the Hospital. Topics in Hosp. Mgmt., 3:77-80, August 1983.

Angaran DM, Dias VC, Arom KV, et al. The Influence of Prophylactic Antibiotics on the Warfarin Anticoagulation Response in the Postoperative Prosthetic Cardiac Valve Patient: Cefamandole vs Vancomycin. Annals Surg., 199:107-111, January 1984.

Ross AD, Angaran DM. Colloids vs. Crystalloids – A Continuing Controversy. Drug Intell. Clin. Pharm., 18:202-212, March 1984.

Angaran DM. Pharmacists Urged to Assume Responsibility for Monitoring Fluid and Electrolyte Use. Intra Therapy News, 11:21-28, June 1984.

Angaran DM. “Chapter 9: The Pharmacist in Coronary Care and Cardiovascular Surgery Intensive Care,” in Practice of Critical Care Pharmacy. Majerus TA and Dasta JF, Editors, Aspen, Rockville, MA 1985, 187-206.

Angaran DM. Monitoring Fluid and Electrolytes, Part I, Vol. 1, #2 and Part II, Vol. 1, #3. Audiotape, Pharmafacts '85, Ottawa, Ontario, Canada.

Schultz N, Angaran DM. Thrombolytic Therapy for Acute Myocardial Infarction, Minn. Pharm., 6-13, April 1985.

Angaran DM, Schultz NJ, Tschida VH. Esmolol – An Ultrashort-acting B-Adrenergic Blocking Agent. Clin. Pharm., 5:288-303, April 1986.

Angaran DM. Career Patterns Among The Pioneers. Am. J. Hosp. Pharm., 43:2747-2750, November 1986.

Reid LD, Angaran DM, Neveaux J. What Patients Want to Know From Pharmacists: Suggestions for Pharmacy Education. Am. J. Pharm. Educ., 50:235-239 (Fall) 1986.

MAJOR PUBLICATIONS

RESEARCH AND REVIEW

Allin D, Anderson S, Angaran DM, et al. Intravenous Esmolol for the Treatment of SVT: Results of a Multicenter, Baseline Controlled Safety and Efficacy Study in 160 Patients. Am. Heart J., 112:498-505, September 1986.

Angaran DM, Dias V, Arom KV et al. The Comparative Influence of Prophylactic Antibiotics on the Prothrombin Response to Warfarin in the Postoperative Prosthetic Valve Patient. Ann. Surg., 206:155-161, 1987.

Angaran DM. Pharmacologic and Pharmacokinetic Comparison of Anti-anginal Agents. Pharmacoth 7(7): S-62-71, 1987.

Angaran DM, Hepler CD, Bjornson D, Hadsall R. Career Patterns of Pioneer Clinical Pharmacists. Am. J. Hosp. Pharm., 45:101-108, January 1988.

Angaran DM, Fuhs DW. Critical Care: A Basic Bibliography (#33). Hosp. Pharm. 1988:23.

Pharmacotherapy: A Pathophysiologic Approach. DiPiro, Talbert, Hayes, Yee and Posey, Editors, Elsevier Science Publishing Company, Inc., 1988:

MAJOR PUBLICATIONS

RESEARCH AND REVIEW

Pharmacotherapy: A Pathophysiologic Approach: 1st edition.

Schultz NJ, Angaran DM: Body Electrolyte Homeostasis, Chapt. 102

Watson MJ, Angaran DM: Acid Base Disorders, Chapt. 103

Angaran DM: Hypovolemia, Chapt. 104

Noer B, Angaran DM. Oxygen delivery and consumption as therapeutic parameters in critically ill. Wellcome Trends in Hospital Pharmacy. 1:2-9, 1989.

Angaran DM. Measuring and monitoring health care. Current Concepts in Pharmacy Management, 11:4-7, 1989.

Angaran DM. Esmolol. Critical Care Outlook, 2:3-5, 1989.

Angaran DM. Informed consent: Ethical issues and future challenges in clinical education. Am. J. Pharm. Educ., Winter 1989.

Rommel RP, Copa AK, Angaran DM. The effects of hemodilution, pH, and protamine on lidocaine plasma protein binding and red blood cell uptake in vitro. Pharm. Res. (in press).

Angaran DM. Measuring and monitoring health care. Top Hosp. Pharm. Manage. 1990; 10:1-11.

Angaran DM, Enright SM. Issue Editors, Pharmaceutical Care, Outcomes, and Quality. Top Hosp. Pharm. Manage. 1990; 10:1-77.

Naylor SM, Fuhs D, Angaran DM. Oxygen Homeostasis: Theory, Measurement, and Therapeutic Implications. DICP, The Annals of Pharmacotherapy. 1990; 24:1195-1203.

Angaran DM. Selecting, developing, and evaluating indicators. Am J Hosp Pharm. 1991 Sep;48(9):1931-7.

Angaran DM. Quality Assurance to Quality Improvement: Measuring and Monitoring Pharmaceutical Care, Am. J. Hosp. Pharm., 1991; 48:1901-7.

Angaran DM. Indicator Selection, Development, and Evaluation. Am. J. Hosp. Pharm. 1991; 48:1931-7.

Drug Usage Evaluations & Clinical Outcome Indicators: 4 PERFORMANCE INDICATORS: AN OVERVIEW, Video Tape December 1991.

Rommel R, Copa AK, Angaran DM. The effects of hemodilution, pH, and protamine on lidocaine plasma protein binding and red blood-cell uptake in vitro. Pharm Res. 1991 Jan;8(1):127-30

Angaran DM, Kilroy R. Acid Base Disorders in Pharmacotherapy: A Pathophysiological Approach, Editors DiPiro, Talbert, Hayes, Yee, Posey, and Matzke, 2nd Edition, 1992.

Angaran DM, Rector TM. Measuring and Monitoring Health Care in Pharmacotherapy: A Pathophysiological Approach, Editors DiPiro, Talbert, Hayes, Yee, Posey, and Matzke, 2nd Edition, 1992.

Sypniewski, E., Angaran, DM. Shock: A Pathophysiological Approach, Editors DiPiro, Talbert, Hayes, Yee, Posy, and Matzke, 2nd Edition, 1992.

Angaran DM. Ensuring Quality Pharmaceutical Care, Through Performance Indicators, Upjohn Current Concepts 1992.

Erwin WG, Angaran DM. Retiree health care: a new model for improving health and reducing costs. Empl Benefits J. 1997 Jun;22(2):2-4.

Angaran DM. Telemedicine and telepharmacy: current status and future implications. Am J Health Syst Pharm. 1999 Jul 15;56(14):1405-26

Angaran DM. Clinical pharmacy saves money and lives--so what's new? Pharmacotherapy. 1999 Dec;19(12):1352-3.

Angaran DM, et al. Clinical pharmacy: looking 20 years back... looking 20 years forward. Pharmacotherapy. 2000 Oct;20(10 Pt 2):235S-242S.

French DD, Campbell R, Sephar A, Angaran DM. Benzodiazepines and injury: a risk adjusted model. Pharmacoepidemiol Drug Saf. 2005 Jan;14(1):17-24.

BRIEF COMMUNICATIONS – ABSTRACTS

Angaran DM: The Experts – Editorial, Drug Intell. Clin. Pharm. 9:114, April 1975.

Angaran DM: My Son – The Clinical Pharmacist. Drug Intell. Clin. Pharm. 9:298-299, June 1975.
Reprinted: South African Journal of Pharmacy, Pharmaceutical Journal of New Zealand, Kansas Journal of Pharmacy, Journal of Irreproducible Results, South Carolina Journal of Pharmacy, Maryland Journal of Pharmacy, San Diego Pharmacist, American Druggist, Revco Pharmaceutical Corp.

Angaran DM. A White Coat, Name Tag and Beeper, Drug Intell. Clin. Pharm. 9:566-567, October 1975.
Reprinted in Kansas Journal of Pharmacy.

Angaran DM. A Clinical Pharmacist's Response to Dr. Knapp's Presentation. Am. J. Pharm. Ed., December 1975.

Angaran DM. Cynic Commission. Drug Intell. Clin. Pharm., 10:394-395, July 1976.

Angaran DM. Random Thoughts. Drug Intell. Clin. Pharm. 10:463, August 1976.

Angaran DM. Let's Objectively Evaluate Clinical Pharmacy. Am. J. Hosp. Pharm. 37:933, July 1980.

Angaran DM. The Tenuring. Drug Intell. Clin. Pharm., 15:494, June 1981.

Angaran DM. The Big Extrapolation. Am. J. Hosp. Pharm., 38:1288, September 1981.

Angaran DM. The Mistake. Am. J. Hosp. Pharm. 38:1286-1288, September 1981.

Angaran DM. Therapy Consultation. Beta blockers after aortocoronary bypass surgery. Clin. Pharm.

1:103, March-April 1982.

Angaran DM. Reflections – My Magic Pill. Am. J. Hosp. Pharm. 9:1548, September 1982.

Angaran DM. Clinical Pharmacy in the United Kingdom. Br. J. Pharm. Pract., 2:25-28, 30, March 1983.

BRIEF COMMUNICATIONS – ABSTRACTS

Angaran DM. Reflections – Writing Without References – My Ambivalence. Am. J. Hosp. Pharm., 40:1044-1045, June 1983.

Angaran DM. Reflections – Re-searching. Am. J. Hosp. Pharm., 40:1689, October 1983.

Angaran DM. Reflections – The Circle. Am. J. Hosp. Pharm., 41:151, January 1984.

Angaran DM. Reflections – The Heartbreak of Serratia, Am. J. Hosp. Pharm., 41:322, February 1984.

Angaran DM. Reflections – I Will Never Sing for My Father. Am. J. Hosp. Pharm., 41:772, April 1984.

Angaran DM. Reflections – The Argument: Who Won? Am. J. Hosp. Pharm., 41:1855, September 1984.

Angaran DM. Reflections – DRG: Dead, Recovered, or Gone. Am. J. Hosp. Pharm., 42:389-390, February 1985.

Angaran DM. Reflections – The Fire Was Confined to ... Am. J. Hosp. Pharm., 42:632, March 1985.

Angaran DM. Reflections – The Fun is Gone. Am. J. Hosp. Pharm., 42:1754, August 1985.

Baillie GR, Angaran DM. Evaluation of the Use and Outcome of Serum Digoxin Assays. Pharmaceutical J., 236:392-393, March 29, 1986.

Angaran DM. What Pharmacy School Didn't Teach You, But Your Mother Talked About. Pharmafacts Audio Tapes. Ontario, Canada, March 1986.

Angaran DM. Reflections. What Was Unsaid. Am. J. Hosp. Pharm. 43:2853. November 1986.

Angaran DM. Reflections. Dreams For Sale. Am. J. Hosp. Pharm. 45:1576. July 1988.

Angaran DM. Reflections. Hand in Hand. Am. J. Hosp. Pharm. 45:1938, 1988.

Gonzalez ER, Dasta J, Angaran D, Gouveia W, Powell JR. Cost and formulary factors in stress ulcer prophylaxis. J. Critical Care Illness September 1988.

Angaran DM. W.D. Shut-Up. Executive Update January 1989.

Angaran DM, Elenbaas RM. Reflections on the history of clinical pharmacy. Videotape 1989, Marion Laboratories.

Angaran DM, Elenbaas RM. The modern history of clinical pharmacy in the United States: An annotated time line, 1910-1989. ACCP Kansas City. 1989.

Angaran DM. The JCAHO Agenda for Change: An Interview With James S. Roberts, M.D. Administrative & Practice Trends in Pharmaceutical Care 1990; 1(1):12-16.

Angaran DM. The Triad in Quality Assessment: Structure, Process, and Outcome. Administrative & Practice Trends in Pharmaceutical Care. 1990; 1(2):9-11.

Angaran DM. Making a Difference: Outcomes, Definition, and Assessment. Administrative & Practice Trends in Pharmaceutical Care. 1990; 1(3):8-11.

Angaran DM. Reflections: Full disclosure. Am J Health-Syst Pharm 2007; 64: 1331-2

Angaran DM. Near Misses and Incidents. Am J Health Syst Pharm. 2012 ;69(3):256-8

Angaran DM. My Life: Marking Time Am J Health-Syst Pharm 2012;69:1695-7

BRIEF COMMUNICATIONS – ABSTRACTS

Angaran DM. Indicators to Improve the Quality of Care. Administrative & Practice Trends in Pharmaceutical Care. 1990; 1(4):8-11.

Angaran DM. Quality Assessment and Continuous Improvement: 1990 in Review. Partners in Pharmaceutical Care. 1991; 1(1):7-10.

Angaran DM. The Medication Use Task Force: A First Look. Partners in Pharmaceutical Care. 1991; 1(2)

Dasta J, Angaran DM. Evolving Role of the Pharmacist in Critical Care, Editorial, Critical Care Medicine 1992; 5:563-565.

Angaran DM. The Other Side of the Gurney, Partners in Pharmaceutical Care 1991; 1(3):6-8.

Angaran DM. Rector TS: Performance Indicator Selection, Development and Evaluation. Partners in Pharmaceutical Care 1992:1(4)9-11.

Dasta JF, Angaran DM. Evolving role of the pharmacist in critical care. Crit Care Med. 1992 May;20(5):563-5.

Angaran DM. Reflections. Full Disclosure. Am J Health-systems Pharm 2007 (in Press)

HONORS AND AWARDS

Nicholas C. Tucci Lecture; University of Pittsburg College of Pharmacy; January 25, 2011

The Philip C. and Ethel F. Ashby Lecture Series University of Oklahoma College of Pharmacy Invited lecture; Medicare Part D. Do NO Economic Harm. January 29, 2008

Crystal Apple Award for Excellence in Advanced Pharmacy Practice Experience, presented at the 2007 AACP Annual Meeting.

Distinguished Leadership of Health-System Pharmacy Practice **2006** presented by the American Society of Health-System Pharmacist.

Awarded best paper of 2006: French DD, Campbell R, Sephar A, Angaran DM. Benzodiazepines and injury: a risk adjusted model. Pharmacoepidemiol Drug Saf. 2005 Jan;14(1):17-24.

Durant Award-1998 University of Wisconsin Hospitals and Clinics Pharmacy Masters Program Career Award

Melendy Lecture Award. University of Minnesota College of Pharmacy- 1999

American Society of Health-Systems Pharmacist Fellowship-1993

Kremmers' Rho Chi Lecture – 1992. University of Wisconsin, School of Pharmacy.

Phi Lambda Sigma, Iota Chapter – March 1992.

Robert G. Leonard Memorial Lecture TSHP – 1992.

ASHP, Quality Assessment and Improvement Using Performance Indicators – June 1992.

ACCP Education Award – 1991.

ACCP Fellowship – (FCCP) August 1990.

JCAHO Fellowship, September 1989 – February 1990.

Board of Directors, ASHP, 1988-1991.

Halley Bruce Memorial Lecture Pharmacy Award by the Minnesota Society of Hospital Pharmacists, 1988.

Secretary, Pharmacy Practice Session of AACP, 1987-1988.

Lyman Research Award, AACP, 1986-1987.

United and Children's Hospitals' Entrepreneurial Silver Medal Award, 1987.

Visiting Lecturer, SUNY-B College of Pharmacy, April, August 1987.

Chairman, Adult Clinical Special Interest Group of ASHP, 1985-1986.

ASHP, Directions for Clinical Practice in Pharmacy, Hilton Head, South Carolina, February 1985.

Sabbatical, University of Minnesota, September 1984-1985.

Preceptor of Student: Virgil Dias, 1982 Student Award from the American Society of Hospital Pharmacy Research and Education Foundation for the paper: "The Influence of Prophylactic Antibiotics on the Warfarin Anticoagulation Response in the Postoperative Prosthetic Cardiac Valve Patient: Cefamandole versus Vancomycin."

Upjohn Visiting Professor, Ohio State College of Pharmacy, September 1982.

Keynote Speaker, United Kingdom Clinical Pharmacist Association, Manchester, England, October 1982.

Clinical Pharmacy Professor of the Year, University of Minnesota, College of Pharmacy, 1981, 1984.

Geigy Visiting Professor, University of Manchester, Department of Pharmacy, Manchester, England, August 1978 – January 1979.

Teacher of the Year, University of Wisconsin School of Pharmacy, 1972.